Diagnosis of Coccidioidomycosis with the Second-Generation Miravista IgG and IgM Enzyme Immunoassay and the Role of Adding Miravista Coccidioides Antigen Detection to Immunodiagnostic Assays
Medical Mycology · 04.07.2024 · 62 (7)
DOI: 10.1093/mmy/myae063 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Medical Mycology, online erschienen am 13.06.2024. Verfasst von Christelle Kassis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Valleywise Health Medical Center, 85008 Phoenix, Arizona. Hauptthemen laut MEDLINE: Coccidioidomycosis, Antigens, Fungal, Immunoglobulin M, Immunoglobulin G. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: MiraVista Diagnostics.
Abstract (Originalsprache)
In the present study, we validate and compare the second-generation Miravista Coccidioides IgG and IgM enzyme immunoassays (EIA) (MiraVista Diagnostics [MVD] Ab EIA) to Meridian Diagnostics Coccidioides IgG and IgM EIA (Meridian Ab EIA), immunodiffusion (ID) and complement fixation (CF). We also evaluated whether the addition of Coccidioides antigen testing to anti-Coccidioides antibody testing increased the sensitivity for the diagnosis of currently active coccidioidomycosis. We retrospectively studied 555 patients evaluated at Valleywise Health Medical Center between January 2013 and May 2017 for whom coccidioidomycosis was suspected and samples were submitted to MVD for testing. Specimens were tested for antigen in the MVD antigen enzyme immunoassay (MVD Ag EIA) and for IgG and IgM antibodies with MVD and Meridian Diagnostics EIAs. ID and CF were obtained from medical records. Sensitivity and specificity were 83.0% and 91.1% or MVD Ab EIA, 69.3% and 99.7% for Meridian Ab EIA, 85.4% and 100% for ID and 65.5% and 100% for CF. Combined MVD antigen and antibody detection by EIA and ID resulted in increased sensitivity in disseminated and pulmonary disease (MVD Ag/MVD Ab: 100%, 88.3%; MVD Ag/Meridian Ab: 98.2%, 78.6%; and MVD Ag/ID: 100%, 91.7%). The detection of antibodies by MVD EIA was more sensitive than Meridian EIA or CF but similar to ID. This study supports the use of antigen testing in immunocompromised patients and those with suspected disseminated disease. Furthermore, the addition of antigen detection by EIA to antibody detection resulted in higher sensitivity of all serological tests.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Valleywise Health Medical Center, 85008 Phoenix, Arizona.
- MiraVista Diagnostics, 46241, Indianapolis, Indiana, USA.
- Department of Medicine, Indiana University School of Medicine, 46202, Indianapolis, Indiana.
ORCID-Profile: Barros Nicolas
Förderung
- MiraVista Diagnostics
Zitieren
APA
Kassis, C., Eric, H., Nicolas, B., John, W., Christopher, D., Cody, B., Kendra, C., Shanna, N., Mary, M., & Joseph, W. L. (2024). Diagnosis of Coccidioidomycosis with the Second-Generation Miravista IgG and IgM Enzyme Immunoassay and the Role of Adding Miravista Coccidioides Antigen Detection to Immunodiagnostic Assays. Medical Mycology, 62(7). https://doi.org/10.1093/mmy/myae063
Vancouver
Kassis C, Eric H, Nicolas B, John W, Christopher D, Cody B, et al. Diagnosis of Coccidioidomycosis with the Second-Generation Miravista IgG and IgM Enzyme Immunoassay and the Role of Adding Miravista Coccidioides Antigen Detection to Immunodiagnostic Assays. Medical Mycology. 2024;62(7). doi:10.1093/mmy/myae063
BibTeX
@article{Kassis2024,
author = {Kassis, Christelle and Eric, Holbrook and Nicolas, Barros and John, Witt and Christopher, Dailey and Cody, Banks and Kendra, Carlson and Shanna, Noveroske and Mary, Murlow and Joseph, Wheat L},
title = {Diagnosis of Coccidioidomycosis with the Second-Generation Miravista IgG and IgM Enzyme Immunoassay and the Role of Adding Miravista Coccidioides Antigen Detection to Immunodiagnostic Assays},
journal = {Medical Mycology},
year = {2024},
volume = {62},
number = {7},
doi = {10.1093/mmy/myae063}
}
EUVIMED